Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer: Safety, Efficacy, and Quality of Life
Official title: Hypofractionated Endometrial Radiation Outcomes and Safety
Run by McGill University Health Centre/Research Institute of the McGill University Health Centre · NCT07871838 · Data updated 2026-11-12
This study tests whether a shorter course of pelvic radiotherapy is safe and effective for women with non-metastatic endometrial cancer, and how it affects their quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | March 7, 2025 |
| Main results expected | August 2030 |
| Study ends | August 2035 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT07871838 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older with newly diagnosed, non-metastatic endometrial cancer (various histologies) who have had surgery and are planned for adjuvant pelvic radiotherapy.
✕Probably not a fit
Patients who have contraindications to radiotherapy, extensive disease beyond the pelvis, or inability to tolerate hypofractionated dosing may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an interventional study evaluating a hypofractionated radiotherapy regimen given after surgery for endometrial cancer. Participants receive 5 radiation treatments on alternating days, with follow-up visits and quality-of-life assessments over five years. The main goal is to see short- and long-term side effects and cancer control, alongside patient-reported outcomes. Eligible patients include adults with newly diagnosed, non-metastatic endometrial carcinoma who have had definitive surgery and meet specific surgical and disease criteria. Safety and efficacy will be monitored through standard tests, imaging, and questionnaires during the study period.
Why it matters
Potential benefit: If successful, this approach could shorten treatment time and maintain safety and effectiveness, potentially improving convenience and reducing costs for patients.
How similar studies have gone: Other studies in similar radiotherapy approaches show promise, but data in gynecologic cancers are limited, making this investigation exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 18 years of age or older, ECOG 0-2. * Newly diagnosed endometrial carcinoma, including endometrioid, serous, clear cell, carcinosarcoma, and dedifferentiated tumours. * FIGO 2009 stage I-IIIC1 are eligible. 20. * Patients will have had previous total hysterectomy + bilateral salpingo-oophorectomy + sentinel lymph node biopsy or pelvic nodal dissection, will be fully debulked (R0 resection). * Have an indication for adjuvant pelvic radiotherapy by the attending radiation oncology physician at tumour board discussion. Exclusion Criteria: * ECOG 3 or higher. * Para-aortic nodal disease. * Non-standard surgery, evidence of residual disease after surgery. * Need of a radiotherapy field exceeding the whole pelvis. * Active inflammatory bowel disease. * Active scleroderma. * Previous cancer in the last 5 years (except non-melanoma skin cancer). * Patients with contraindication to CT contrast. * Inability to achieve dose constraints. * Inability to reproduce simulation positioning during treatment.
Where it's running
-
McGill University Health Centre--Cedars Cancer Centre
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Joanne Alfieri, MD — McGill University Health Centre/Research Institute of the McGill University Health Centre
- Study coordinator: Joanne Alfieri, MD
- Email: joanne.alfieri@ssss.gouv.qc.ca
- Phone: 514-934-1934
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One year vs two years of maintenance immunotherapy for endometrial cancer
This trial tests whether keeping pembrolizumab or dostarlimab for one year works as well as two years for people with advanced, recurrent, or metastatic endometrial cancer who completed initial chemo and anti-PD1 therapy.
-
QL1706 therapy for advanced endometrial cancer after PD-1/L1 treatment failure
This study is testing if a new treatment called QL1706, combined with chemotherapy, can help people with advanced endometrial cancer who didn't respond to earlier PD-1/L1 therapy.
-
Personalized navigation to support rural and Black women with endometrial cancer
This pilot tests a tailored patient-navigation program to help rural and Black patients with endometrial cancer access care and services.
-
KRAS Inhibitor ETX-929 in advanced solid tumors
This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.